

Nymox director Robinson continues to buy

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} director James Robinson continued his recent buying spree by investing another \$295,000 in the company.

Robinson continued his recent spate of share purchases by 95,000 shares bought at around \$2.90 per share.

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James George Robinson bought 95,000 shares of the business's stock in a transaction on Friday, January 8th.

The stock was purchased at an average cost of \$2.90 per share, for a total transaction of \$275,500.00. Following the transaction, the director now owns 2,637,550 shares of the company's stock, valued at \$7,648,895. The transaction was disclosed in a document filed with the Securities & Exchange Commission.

James George Robinson also recently made the following trades:

- On Wednesday, December 30th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corp stock. The stock was bought at an average cost of \$3.38 per share, with a total value of \$16,900.00.
- On Tuesday, December 29th, James George Robinson bought 14,000 shares of Nymox Pharmaceutical Corp stock. The stock was bought at an average cost of \$3.55 per share, with a total value of \$49,700.00.
- On Monday, December 28th, James George Robinson bought

6,000 shares of Nymox Pharmaceutical Corp stock. The stock was bought at an average cost of \$3.79 per share, with a total value of \$22,740.00.

Today's Trading

Shares of Nymox traded down 22.97% on Friday, reaching \$2.18. 950,768 shares of the company's stock were exchanged. Nymox Pharmaceutical Corp has a 1-year low of \$0.35 and a 1-year high of \$4.37. The stock's 50-day moving average price is \$3.36 and its 200-day moving average price is \$2.78. The company's market capitalization is \$92.92 million.

Nymox Pharmaceutical Corp Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ([NASDAQ:NYMX](https://www.nasdaq.com/markets/stocks/tickers/NYMEX)) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.